Compositions and methods for treating cancer
A compound and an independent technology, applied in biochemical equipment and methods, chemical equipment and methods, translation products of oncogenes, etc., can solve the problems of reducing GTPase activity, reducing Ras sensitivity, increasing active GTP-binding populations, etc.
- Summary
- Abstract
- Description
- Claims
- Application Information
AI Technical Summary
Problems solved by technology
Method used
Image
Examples
preparation example Construction
[0168]Preparation and screening of combinatorial chemical libraries is well known to those skilled in the art. Such combinatorial chemical libraries include, but are not limited to, peptide libraries (see, e.g., U.S. Patent 5,010,175, Furka, Int. J. Pept. Prot. Res. 37:487-493 (1991) and Houghton et al., Nature 354:84-88 (1991)). Other chemistries for generating chemical diversity libraries can also be used. Such chemicals include, but are not limited to: peptoids (e.g., PCT Publication No. WO 91 / 19735), encoded peptides (e.g., PCT Publication WO 93 / 20242), random biooligomers (e.g., PCT Publication No. WO 92 / 00091), benzodiazepines (e.g., U.S. Patent No. 5,288,514), diversomers such as hydantoins, benzodiazepines, and dipeptides (Hobbs et al., U.S. National Proc. of the Academy of Sciences (Proc.Nat.Acad.Sci.USA)" 90:6909-6913 (1993)), alkene polypeptide (Hagihara et al., "J.Amer.Chem.Soc.)" 114 :6568(1992)), non-peptidic peptide mimetics with glucose backbone (Hirschmann ...
Embodiment P1
[0616] Embodiment P1. A compound having the formula:
[0617] in,
[0618] R 1 are independently halogen, -CX 1 3 , -CHX 1 2 、-CH 2 x 1 ,-OCX 1 3 、-OCH 2 x 1 , -OCHX 1 2 , -CN, -SO n1 R 1D 、-SO v1 NR 1A R 1B , -NHC(O)NR 1A R 1B , -N(O) m1 , -NR 1A R 1B , -C(O)R 1C , -C(O)-OR 1C , -C(O)NR 1A R 1B , -OR 1D , -NR 1A SO 2 R 1D , -NR 1A C(O)R 1C , -NR 1A C(O)OR 1C , -NR 1A OR 1C , substituted or unsubstituted alkyl, substituted or unsubstituted heteroalkyl, substituted or unsubstituted cycloalkyl, substituted or unsubstituted heterocycloalkyl, substituted or unsubstituted substituted aryl or substituted or unsubstituted heteroaryl;
[0619] R 2 are independently halogen, -CX 2 3 , -CHX 2 2 、-CH 2 x 2 ,-OCX 2 3 、-OCH 2 x 2 , -OCHX 2 2 , -CN, -SO n2 R 2D 、-SO v2 NR 2A R 2B , -NHC(O)NR 2A R 2B , -N(O) m2 , -NR 2A R 2B , -C(O)R 2C , -C(O)-OR 2C , -C(O)NR 2A R 2B , -OR 2D , -NR 2A SO 2 R 2D , -NR 2A C(O)R 2C , -NR...
Embodiment P2
[0640] Embodiment P2. The compound of embodiment P1, wherein E is a covalent cysteine modification moiety.
PUM
Login to View More Abstract
Description
Claims
Application Information
Login to View More 


